SPL Stock Overview
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Starpharma Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.66 |
| 52 Week High | AU$1.11 |
| 52 Week Low | AU$0.49 |
| Beta | 0.87 |
| 1 Month Change | 19.09% |
| 3 Month Change | 22.43% |
| 1 Year Change | -37.62% |
| 3 Year Change | -45.19% |
| 5 Year Change | -59.06% |
| Change since IPO | -18.13% |
Recent News & Updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation
Nov 22
Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money
Mar 21We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely
Jan 26We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth
Jun 21Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?
May 16Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation
Mar 02Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?
Feb 10
Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future
Jan 20Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?
Dec 28How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?
Dec 07Shareholder Returns
| SPL | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -6.4% | -4.4% | 0.6% |
| 1Y | -37.6% | -25.2% | 3.5% |
Return vs Industry: SPL underperformed the Australian Pharmaceuticals industry which returned -25.2% over the past year.
Return vs Market: SPL underperformed the Australian Market which returned 3.5% over the past year.
Price Volatility
| SPL volatility | |
|---|---|
| SPL Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: SPL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: SPL's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 50 | Jackie Fairley | https://starpharma.com |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray.
Starpharma Holdings Limited Fundamentals Summary
| SPL fundamental statistics | |
|---|---|
| Market Cap | AU$267.80m |
| Earnings (TTM) | -AU$16.15m |
| Revenue (TTM) | AU$5.16m |
51.9x
P/S Ratio-16.6x
P/E RatioIs SPL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPL income statement (TTM) | |
|---|---|
| Revenue | AU$5.16m |
| Cost of Revenue | AU$14.46m |
| Gross Profit | -AU$9.29m |
| Other Expenses | AU$6.86m |
| Earnings | -AU$16.15m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.04 |
| Gross Margin | -180.05% |
| Net Profit Margin | -312.94% |
| Debt/Equity Ratio | 8.3% |
How did SPL perform over the long term?
See historical performance and comparison